Generic Name and Formulations:
Oxymetazoline HCl 1%; crm.
Indications for RHOFADE:
Persistent facial erythema associated with rosacea.
≥18yrs: apply a pea-sized amount once daily in a thin layer to entire face (forehead, nose, each cheek, chin). Wash hands after use.
<18yrs: not established.
Not for oral, ophthalmic, or intravaginal use. Avoid eyes, lips, irritated skin, or open wounds. Severe or unstable/uncontrolled cardiovascular disease. Orthostatic hypotension. Uncontrolled hypertension or hypotension. Cerebral or coronary insufficiency. Raynaud's phenomenon. Thromboangiitis obliterans. Scleroderma. Sjögren's syndrome. Increased risk of angle closure glaucoma. Pregnancy. Nursing mothers.
Caution with concomitant beta-blockers, antihypertensives, cardiac glycosides, alpha-1 receptor antagonists. Concomitant MAOIs may affect the metabolism and uptake of circulating amines; caution.
Application site reactions (eg, dermatitis, pruritus, erythema, pain), worsening inflammatory lesions of rosacea.
Gel—30g, 60g (tube or pump)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML